Page contents Full notification Final report General information GMO characterization European Commission administrative Information Return to search

Full notification Final report - General information Notification Number B/NL/21/015 Member State to which the notification was sent Netherlands Date of acknowledgement from the Member State Competent Authority 17/06/2021 Title of the Project Clinical testing of TX200-TR101, an autologous antigen-specific chimeric antigenreceptor (CAR) T regulatory cell therapy. Proposed period of release: 01/03/2020 to 31/12/2041 Name of the Institute(s) or Company(ies) Sangamo Therapeutics France SAS
Is the same GMO been notified elsewhere by the same notifier? Yes:
Belgium; Germany; France; United Kingdom; Has the same GMO been notified elsewhere by the same notifier? Yes If yes, notification number(s): GMO characterization GMO is a: Other Identity of the GMO: The GMO / IMP consists of human regulatory T cells transduced ex vivo with areplication-deficient self-inactivating lentiviral vector carrying a genetic elementencoding the expression of a Chimeric Antigen Receptor (CAR). Information relating to the recipient or parental organisms from which the GMO is derived Common Name: Human Genus: Human Species: Homo Sapiens Subspecies: Strain: Pathovar: European Commission administrative Information Consent given by the Member State Competent Authority: Yes
06/07/2021